Related Experiment Video
Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Drug Development
Federica Cacciamani1,2, Graziella Mangin Laignel2, Audrey Gabelle3,4
1ARAMISLab, Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, CNRS, Inria, Inserm, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France, France.
Background:
Recruiting participants for research studies on early-stage Alzheimer's disease (AD) is challenging yet crucial for advancing research and timely interventions. DocMemo, a digital platform for individuals with memory concerns in France (docmemo.fr) and the US (docmemo.com), provides cognitive screening, helps schedule memory-related visits, and allows users to express interest in research participation. We evaluated how effectively DocMemo can help identify potential research participants by examining how many users agreed to be recontacted, and factors associated with this agreement overall and within each country.
Method:
Demographic, cognitive, psychological, health-related, and lifestyle data, as well as country, were collected from users interacting with DocMemo (i.e., completing cognitive health questionnaires or scheduling medical visits). All users were asked whether they agreed to be recontacted for future research opportunities (yes/no). Multivariable logistic regressions were used to identify factors linked to this agreement within each country, accounting for multiple comparisons.
Result:
We recorded 13,043 unique users (France: 9,446 from 13-07-2024 to 24-01-2025; US: 35,97 from 22-10-2024 to 24-01-2025). Their characteristics are detailed in Table 1. The proportion of users agreeing to be recontacted for future research was 20.09% in France and 13.09% in the US. In both countries, agreement was significantly associated with older age (France: OR=1.08, p=0.015; US: OR=1.20, p=0.011), more cognitive complaints (CFI score, France: OR=1.20, p<0.001; US: OR=1.20, p=0.002), and depression (France: OR=1.25, p=0.004; US: OR=1.37, p=0.042). In France, agreement was also higher among females (OR=1.19, p=0.008), those with high education (OR=1.52, p<0.001), and those with a family history of AD (OR=1.33, p<0.001). Other factors were not significantly associated with agreement in either country (p>0.05, Table 2).
Conclusion:
DocMemo provides a steady stream of individuals at risk for ADRD who express interest in research participation. This pool of potential participants can help meet recruitment needs for multiple studies simultaneously.
More Related Videos
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
Related Concept Videos
Preclinical Development: Overview
Clinical Trials: Overview
Drug Discovery: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
In Vitro Drug Release Testing: Overview, Development and Validation
Drug Regulation